Skip to main content
. Author manuscript; available in PMC: 2015 Aug 18.
Published in final edited form as: Nat Rev Clin Oncol. 2011 Mar 1;8(4):210–221. doi: 10.1038/nrclinonc.2011.21

Table 1.

Successful completed phase III trials with anti-VEGF pathway agents

Combined with Tumor (setting) ↑ PFS? ↑OS? Trial identifier
Bevacizumab
FOLFIRI CRC (1st) Yes Yes* AVF210796
FOLFOX or XELOX CRC (1st) Yes* Yes NO1696615
FOLFOX CRC (2nd) Yes Yes* E320097
Paclitaxol MBC (1st) Yes* No E210098
Docetaxol MBC (1st) Yes* NA AVADO99
Capecitabine and taxane or anthracycline MBC (1st) Yes* No Ribbon1100
Chemotherapy MBC (2nd) Yes* NA Ribbon2101
Carboplatin and paclitaxel NSCLC (1st) Yes Yes* E4599102
Cisplatin and gemcitabine NSCLC (1st) Yes* No AVAiL103
Erlotinib NSCLC (2nd) Yes* NA ATLAS104
Interferon-2α RCC (1st) Yes No* AVOREN105
Interferon-2α RCC (1st) Yes No* CALGB90206106
Carboplatin and paclitaxel OC (1st) Yes* NA GOG 021837
Monotherapy GBM (2nd)§ Yes Yes AVF3708107
Sunitinib
Monotherapy RCC (1st) Yes* Yes NCT00083889108
Monotherapy GIST (2nd) Yes NA SUN 1112109
Monotherapy PIC (2nd) Yes* Yes NCT00428597110
Sorafenib
Monotherapy RCC (1st) Yes No*# TARGET111
Monotherapy HCC (1st) No Yes* SHARP112
Pazopanib
Monotherapy RCC (1st and 2nd) Yes* NA VEG105192113
Vandetanib
Docetaxol NSCLC (2nd) Yes* NA ZODIAC114
*

Primary end point.

Various chemotherapies including paclitaxel, protein-bound paclitaxel, docetaxel, gemcitabine, capecitabine, and vinorelbine.

§

A phase II trial.

Study evaluated the outcome of each arm relative to historical control.

Objective response rate improved.

#

Benefit seen with crossover.

Abbreviations: ↑, increased; 5-fluorouracil, 5-FU; CRC, colorectal cancer; FOLFOX, 5-FU, leucovorin and oxaliplatin; FOLFIRI, 5-FU, leucovorin and irinotecan; GBM, glioblastoma muliforme; GIST, gastrointestinal stromal tumors; HCC, hepatocellular carcinoma; MBC, metastatic breast cancer; NA, not available (pending, unknown or not reported); NSCLC, non-small-cell lung cancer; OC, ovarian cancer; OS, overall survival; PFS, progression-free survival; PIC, pancreatic islet cell; RCC, renal cell carcinoma; XELOX, capecitabine and oxaliplatin.